

# Satoshi Yuki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3372069/publications.pdf>

Version: 2024-02-01

130  
papers

1,058  
citations

566801

15  
h-index

500791

28  
g-index

136  
all docs

136  
docs citations

136  
times ranked

1498  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1899-1903.	15.2	110
2	Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. <i>Gastric Cancer</i> , 2016, 19, 183-191.	2.7	95
3	Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 566-571.	0.6	67
4	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	3.2	62
5	Prognostic and Predictive Value of HER2 Amplification in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, 198-205.	1.0	57
6	Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. <i>British Journal of Cancer</i> , 2017, 117, 1450-1458.	2.9	52
7	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	3.2	44
8	Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4100-4100.	0.8	40
9	Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. <i>Cancer Science</i> , 2015, 106, 891-895.	1.7	39
10	Association of early tumor shrinkage with progression-free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802.. <i>Journal of Clinical Oncology</i> , 2015, 33, 749-749.	0.8	34
11	A Prospective Observational Study on Effect of Short-Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO-01). <i>Oncologist</i> , 2017, 22, 592-600.	1.9	30
12	Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100535.	1.5	29
13	The Prognostic Impact of KRAS G12C Mutation in Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Observational Study. <i>Oncologist</i> , 2021, 26, 845-853.	1.9	26
14	Prognostic Value and Molecular Landscape of HER2 Low-Expressing Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 113-120.e1.	1.0	22
15	One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. <i>Oncologist</i> , 2019, 24, 1593-1600.	1.9	21
16	REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2021, 21, 674.	1.1	19
17	Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy. <i>BMC Cancer</i> , 2019, 19, 255.	1.1	16
18	Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095686.	1.4	16

#	ARTICLE	IF	CITATIONS
19	Safety analysis of FOLFOX as adjuvant chemotherapy for stage III colon cancer in phase II study (NORTH/HGCSG1003): Detailed analysis of peripheral sensory neuropathy.. Journal of Clinical Oncology, 2015, 33, 701-701.	0.8	15
20	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. BMC Cancer, 2015, 15, 626.	1.1	13
21	Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemotherapy and Pharmacology, 2020, 85, 217-223.	1.1	13
22	The nationwide cancer genome screening project in Japan SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced gastric cancer (GC).. Journal of Clinical Oncology, 2018, 36, 4050-4050.	0.8	13
23	Voltage: Investigator-initiated clinical trial of nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable locally advanced rectal cancer.. Journal of Clinical Oncology, 2019, 37, 3606-3606.	0.8	12
24	Plasma <i>RAS</i> dynamics and anti-EGFR rechallenge efficacy in patients with <i>RAS/BRAF</i> wild-type metastatic colorectal cancer: REMARRY and PURSUIT trials.. Journal of Clinical Oncology, 2022, 40, 3518-3518.	0.8	11
25	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology, 2018, 36, 3530-3530.	0.8	10
26	Large-scale analyses of tumor mutation burdens (TMBs) across various advanced gastrointestinal (GI) malignancies in the nationwide cancer genome screening project, SCRUM-Japan GI-SCREEN.. Journal of Clinical Oncology, 2018, 36, 12094-12094.	0.8	9
27	Survival outcome in HER2-amplified metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 642-642.	0.8	9
28	FMSA-like tyrosine kinase 3 ( FLT3 ) amplification in patients with metastatic colorectal cancer. Cancer Science, 2021, 112, 314-322.	1.7	8
29	Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy. JCO Precision Oncology, 2022, 6, e2100383.	1.5	8
30	Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603. Oncologist, 2022, 27, e642-e649.	1.9	8
31	Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer. ESMO Open, 2019, 4, e000584.	2.0	7
32	Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor. Clinical Colorectal Cancer, 2021, 20, e173-e184.	1.0	7
33	Randomized phase II study comparing dose-escalated weekly paclitaxel versus standard dose weekly paclitaxel for patients with previously treated advanced gastric cancer.. Journal of Clinical Oncology, 2013, 31, 4076-4076.	0.8	7
34	Translational research of VOLTAGE-A: Efficacy predictors of preoperative chemoradiotherapy and consolidation nivolumab in patients with both microsatellite stable and microsatellite instability-high locally advanced rectal cancer.. Journal of Clinical Oncology, 2021, 39, 100-100.	0.8	6
35	Updated analysis: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer—HGCSG1401.. Journal of Clinical Oncology, 2017, 35, 778-778.	0.8	6
36	A retrospective multicenter study evaluating the efficacy and safety of irinotecan in patients with advanced gastric cancer: Analysis of albumin-bilirubin (ALBI) grade.. Journal of Clinical Oncology, 2020, 38, 415-415.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Prophylactic Effect of Dexamethasone on Regorafenib-Related Fatigue and/or Malaise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study in Patients with Unresectable Metastatic Colorectal Cancer (KSCC1402/HGCSG1402). <i>Oncology</i> , 2018, 94, 289-296.	0.9	5
38	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer. <i>Cancer Science</i> , 2021, 112, 1567-1578.	1.7	5
39	Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 688709.	1.3	5
40	Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. <i>European Journal of Cancer</i> , 2021, 154, 296-306.	1.3	5
41	Plasma VEGF-D and PIGF levels according to prior use of biologics among metastatic colorectal cancer: Preliminary results from GI-SCREEN CRC-Ukit study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 178-178.	0.8	5
42	Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. <i>Biomedical Reports</i> , 2019, 11, 171-180.	0.9	4
43	Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS). <i>Frontiers in Oncology</i> , 2021, 11, 576036.	1.3	4
44	The Nationwide Cancer Genome Screening Project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3591-3591.	0.8	4
45	Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 169-169.	0.8	4
46	Comparison of cetuximab (Cmab) with panitumumab (Pmab) monotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002.. <i>Journal of Clinical Oncology</i> , 2014, 32, 663-663.	0.8	4
47	A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403). <i>Oncologist</i> , 2021, 26, e1675-e1682.	1.9	3
48	Alleviation of Abdominal Pain due to Irinotecan-Induced Cholinergic Syndrome Using Loperamide: A Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 806-811.	0.3	3
49	Infusion-related reaction to ramucirumab plus FOLFIRI in patients with advanced colorectal cancer. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2025-2028.	1.0	3
50	A randomized, double-blind, placebo-controlled phase II study of prophylactic dexamethasone (dex) therapy for fatigue and malaise due to regorafenib in patient (pts) with metastatic colorectal cancer (mCRC): (KSCC1402/HGCSG1402).. <i>Journal of Clinical Oncology</i> , 2016, 34, 10127-10127.	0.8	3
51	VOLTAGE: Multicenter phase Ib/II study of nivolumab monotherapy and subsequent radical surgery after preoperative chemoradiotherapy with capecitabine in patients with locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS878-TPS878.	0.8	3
52	Translational research of voltage-A1: Efficacy predictors of preoperative chemoradiotherapy and subsequent nivolumab monotherapy in patients with microsatellite-stable locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4073-4073.	0.8	3
53	Scoop: Multicenter phase I/II trial of BBI608 and pembrolizumab in patients with metastatic colorectal cancer (EPOC1503).. <i>Journal of Clinical Oncology</i> , 2020, 38, 107-107.	0.8	3
54	Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience. <i>Journal of Gastric Cancer</i> , 2016, 16, 177.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Hypertriglyceridemia Induced by Fluorouracil: A Novel Case Report. <i>Case Reports in Oncology</i> , 2021, 14, 207-211.	0.3	2
56	Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for Anti-EGFR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 573-573.	0.8	2
57	The nationwide genomic screening project for gastrointestinal cancer in Japan (GI-SCREEN): Simultaneous identification of KRAS, NRAS, BRAF, and PIK3CA mutation in advanced colorectal cancer (aCRC) (GI-SCREEN 2013-01).. <i>Journal of Clinical Oncology</i> , 2015, 33, 578-578.	0.8	2
58	Regorafenib (REG) versus trifluridine/tipiracil (TAS-102) as salvage-line in patients with metastatic colorectal cancer refractory to standard chemotherapies (REGOTAS): A propensity score analysis from a JSCCR multicenter observational study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3540-3540.	0.8	2
59	A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4059-4059.	0.8	2
60	Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS3623-TPS3623.	0.8	2
61	Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205.. <i>Journal of Clinical Oncology</i> , 2017, 35, 151-151.	0.8	2
62	Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201). <i>Oncologist</i> , 2022, 27, 340-e374.	1.9	2
63	The survival benefit of increasing the number of active drugs for metastatic colorectal cancer: A multicenter retrospective study. <i>Cancer Medicine</i> , 2022, , .	1.3	2
64	Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer. <i>Supportive Care in Cancer</i> , 2022, , 1.	1.0	2
65	Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study. <i>International Journal of Clinical Oncology</i> , 2020, 25, 1800-1806.	1.0	1
66	Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3529-3529.	0.8	1
67	Expression of PD-L1 and PD-L2 in colorectal cancer (CRC): A post-hoc integrated analysis of SCRUM-Japan GI-SCREEN CRC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 120-120.	0.8	1
68	Prognostic impact of human epidermal growth factor-2 (HER2) status on overall survival (OS) of advanced gastric cancer (AGC) patients (pts) treated with standard chemotherapy without trastuzumab as a first-line treatment: A Japanese multicenter collaborative retrospective study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4075-4075.	0.8	1
69	Randomized phase II study comparing dose-escalated weekly paclitaxel (wPTX) versus standard-dose wPTX for patients with previously treated advanced gastric cancer (AGC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 64-64.	0.8	1
70	Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 163-163.	0.8	1
71	Clinical impact of expanded BRAF mutational status on the outcome for metastatic colorectal cancer patients with anti-EGFR antibody: An analysis of the BREAC trial (Biomarker Research for) Tj ETQq1 1 0.784314 rgBT /Overlock 10 2015, 33, 11038-11038.	0.8	1
72	The Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan) Tj ETQq0 0 0 rgBT /Overlock 10 and non-colorectal gastrointestinal cancer (GI Screen 2013-01-CRC and 2015-01-Non CRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS4134-TPS4134.	0.8	1

#	ARTICLE	IF	CITATIONS
73	A multicenter phase I/II study of TAS-102 with nintedanib in patients (pts) with metastatic colorectal cancer (mCRC) refractory to standard therapies (N-TASK FORCE): EPOC1410.. Journal of Clinical Oncology, 2016, 34, TPS3632-TPS3632.	0.8	1
74	A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of tumor location.. Journal of Clinical Oncology, 2018, 36, 802-802.	0.8	1
75	Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603.. Journal of Clinical Oncology, 2019, 37, 509-509.	0.8	1
76	Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.. Journal of Clinical Oncology, 2019, 37, 578-578.	0.8	1
77	Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer.. Journal of Clinical Oncology, 2019, 37, 84-84.	0.8	1
78	Randomized phase III clinical study comparing postoperative UFT/LV,UFT+LV/UFT and UFT+LV+PSK/UFT+PSK as adjuvant therapy for curatively resected stage III colorectal cancer HGCSG-CAD study.. Journal of Clinical Oncology, 2013, 31, 3638-3638.	0.8	1
79	Phase II trial of irinotecan plus s-1 (IRIS) with cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS wild-type metastatic colorectal cancer (mCRC): HGCSG0902â€”Comparison of administration interval in cetuximab treatment.. Journal of Clinical Oncology, 2015, 33, 746-746.	0.8	1
80	Prospective observational study for the impact of short-term periodic intravenous steroid premedication for gastrointestinal cancer chemotherapy on bone metabolism.. Journal of Clinical Oncology, 2016, 34, 523-523.	0.8	1
81	The Nationwide Cancer Genome Screening Project for Gastrointestinal Cancer in Japan (GI-SCREEN): MSI-status and cancer-related genome alterations in advanced colorectal cancer (CRC)â€”GI-SCREEN 2013-01-CRC sub-study.. Journal of Clinical Oncology, 2016, 34, 3573-3573.	0.8	1
82	HGCSG 1301: A multicenter, double-blind, randomized controlled phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer treated with IRIS/Bev as second-line therapyâ€”Updated analysis of antitumor efficacy.. Journal of Clinical Oncology, 2020, 38, 108-108.	0.8	1
83	VOLTAGE-B study: Nivolumab monotherapy and subsequent curative surgery following preoperative chemoradiotherapy in patients with locally recurrent rectal cancer (LRRC) without previous radiotherapy.. Journal of Clinical Oncology, 2020, 38, 100-100.	0.8	1
84	Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy. Targeted Oncology, 2022, , 1.	1.7	1
85	Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer. BMJ Open, 2022, 12, e048833.	0.8	1
86	NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN). Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	1
87	Multicenter Cohort Study to Assess the Association between Changes on Imaging and Outcome after Regorafenib Treatment (KSCC1603). Oncology, 2020, 98, 719-726.	0.9	0
88	Evaluating the intratumor microbiome of pancreatic ductal adenocarcinoma (PDAC) by analyzing the fresh frozen tissues obtained by endoscopic ultrasound-guided fine needle aspiration (EUS-FNA).. Journal of Clinical Oncology, 2021, 39, 418-418.	0.8	0
89	Discovery of a potential predictive marker for eribulin treatment and novel target genes in BRAF V600E mutant metastatic colorectal cancer using an AI-driven RNA-seq analysis platform: Translational research of the BRAVERY study (EPOC1701).. Journal of Clinical Oncology, 2021, 39, e15532-e15532.	0.8	0
90	Retrospective cohort study on the risk factors of admission due to serious adverse events during S-1 (tegafur, gimeracil, oteracil potassium) containing chemotherapy for gastric cancer.. Journal of Clinical Oncology, 2012, 30, 141-141.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer: Update analysis of the Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 3593-3593.	0.8	0
92	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis of the Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 460-460.	0.8	0
93	Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial: Comparison of the efficacy of KRAS status. <i>Journal of Clinical Oncology</i> , 2013, 31, 536-536.	0.8	0
94	An open, multicenter, phase II clinical trial to evaluate efficacy and safety of S-1 plus cisplatin in patients with advanced gastric cancer (AGC): HGCSG0702: Safety analysis. <i>Journal of Clinical Oncology</i> , 2013, 31, 121-121.	0.8	0
95	Retrospective cohort study on the safety and efficacy of panitumumab for patients with metastatic colorectal cancer: The HGCSG1002 study: Analysis of adverse events. <i>Journal of Clinical Oncology</i> , 2013, 31, 554-554.	0.8	0
96	The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Analysis of two phase II studies. <i>Journal of Clinical Oncology</i> , 2013, 31, e14604-e14604.	0.8	0
97	Analysis of Kohne's prognostic index in KRAS wild-type patients with metastatic colorectal cancer (mCRC) treated with salvage-line cetuximab-based regimen: HGCSG0901. <i>Journal of Clinical Oncology</i> , 2014, 32, 634-634.	0.8	0
98	Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Tegaserod). <i>Journal of Clinical Oncology</i> , 2014, 32, 1061-1061.	0.8	0
99	Comparison of adding cetuximab (Cmab) or panitumumab (Pmab) to irinotecan (IRI)-based chemotherapy in salvage line against KRAS wild-type patients with metastatic colorectal cancer (mCRC): Analysis of HGCSG0901 and 1002. <i>Journal of Clinical Oncology</i> , 2014, 32, 598-598.	0.8	0
100	The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies. <i>Journal of Clinical Oncology</i> , 2014, 32, 603-603.	0.8	0
101	Exploratory randomized trial to evaluate the effect of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI: HGCSG0704. <i>Journal of Clinical Oncology</i> , 2014, 32, 624-624.	0.8	0
102	Phase II trial of S-1 plus split cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702): Final report. <i>Journal of Clinical Oncology</i> , 2014, 32, 113-113.	0.8	0
103	Randomized controlled trial on the skin toxicity of panitumumab in third-line treatment of KRAS wild-type metastatic colorectal cancer: HGCSG1001 (Japanese Skin Toxicity Evaluation Protocol with Tegaserod). <i>Journal of Clinical Oncology</i> , 2014, 32, 3587-3587.	0.8	0
104	Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status. <i>Journal of Clinical Oncology</i> , 2015, 33, 782-782.	0.8	0
105	Analysis of the GERCOR index in KRAS Exon2 WT patients with mCRC treated with salvage-line cetuximab-based chemotherapy: HGCSG0901. <i>Journal of Clinical Oncology</i> , 2015, 33, 781-781.	0.8	0
106	Association of morphologic response with progression free survival in patients with metastatic colorectal cancer treated with bevacizumab-based chemotherapy: HGCSG0802. <i>Journal of Clinical Oncology</i> , 2015, 33, 743-743.	0.8	0
107	Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Comparison of intravenous FU/oxaliplatin (OX)+BV and oral FU/OX+BV. <i>Journal of Clinical Oncology</i> , 2015, 33, 527-527.	0.8	0
108	Updated analysis: Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status. <i>Journal of Clinical Oncology</i> , 2016, 34, 522-522.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802 Analysis of early tumor shrinkage (ETS).. Journal of Clinical Oncology, 2016, 34, 753-753.	0.8	0
110	Phase II trial of bolus 5-FU/l-LV regimen as salvage line chemotherapy for oral fluorouracil resistant unresectable gastric cancer (HGCSG1502).. Journal of Clinical Oncology, 2016, 34, TPS177-TPS177.	0.8	0
111	Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the GERCOR index.. Journal of Clinical Oncology, 2016, 34, 743-743.	0.8	0
112	Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902 Comparison of administration interval in cetuximab treatment.. Journal of Clinical Oncology, 2016, 34, 771-771.	0.8	0
113	Update analysis: Prospective observational study for the impact of short-term periodic steroid premedication for cancer chemotherapy on bone metabolism ESPRESSO-01 study.. Journal of Clinical Oncology, 2016, 34, e18145-e18145.	0.8	0
114	A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting: ESPRESSO-02/HGCSG1602.. Journal of Clinical Oncology, 2017, 35, TPS809-TPS809.	0.8	0
115	North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003).. Journal of Clinical Oncology, 2017, 35, 807-807.	0.8	0
116	Systematic review and individual patient data based meta-analysis of palonosetron trials for chemotherapy induced nausea and vomiting.. Journal of Clinical Oncology, 2017, 35, e21688-e21688.	0.8	0
117	The Nationwide Cancer Genome Screening Project in Japan SCRUM-Japan, GI-screen: Efficient identification of cancer genome alterations in advanced gastric cancer.. Journal of Clinical Oncology, 2017, 35, 4041-4041.	0.8	0
118	A Case Report of Successful Conversion Therapy with XELOX + Bevacizumab in a Patient with AFP-producing Colon Cancer and Synchronous Liver Metastases. Nihon Gekakei Rengo Gakkaiishi (Journal of Japanese College of Surgeons), 2018, 43, 845-854.	0.0	0
119	A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer (HGCSG1503): Analysis of cases of prior regorafenib.. Journal of Clinical Oncology, 2018, 36, 832-832.	0.8	0
120	Multicenter phase I/III trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.. Journal of Clinical Oncology, 2018, 36, 760-760.	0.8	0
121	Safety of administration of bevacizumab within a week from placement of a totally implantable central venous port system.. Journal of Clinical Oncology, 2018, 36, 589-589.	0.8	0
122	Predictive value of tumor growth rate during previous treatment for tumor response to regorafenib (REGO) and trifluridine/tipiracil (TFTD) in metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology, 2018, 36, 766-766.	0.8	0
123	The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit.. Journal of Clinical Oncology, 2018, 36, TPS885-TPS885.	0.8	0
124	Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.. Journal of Clinical Oncology, 2018, 36, 10094-10094.	0.8	0
125	A retrospective analysis of neoadjuvant chemotherapy followed by surgery or definitive chemoradiotherapy in patients with advanced esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2019, 37, 115-115.	0.8	0
126	Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer.. Journal of Clinical Oncology, 2019, 37, 359-359.	0.8	0



#	ARTICLE	IF	CITATIONS
127	HGCSG 1603: Phase II study of ramucirumab and irinotecan combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer.. Journal of Clinical Oncology, 2019, 37, TPS183-TPS183.	0.8	0
128	HGCSG 1803: Single-arm phase II study evaluating efficacy of oxaliplatin, irinotecan and S-1 combination therapy (OX-IRIS) in metastatic pancreatic cancer as first-line treatment.. Journal of Clinical Oncology, 2020, 38, TPS4668-TPS4668.	0.8	0
129	The impact of single-hetero UGT1A1 on clinical outcomes of irinotecan monotherapy in gastric cancer after fluoropyrimidine, platinum, and taxanes: Multicenter retrospective study.. Journal of Clinical Oncology, 2020, 38, 296-296.	0.8	0
130	Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in <i>RAS</i> wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.. Journal of Clinical Oncology, 2022, 40, 3530-3530.	0.8	0